Strengthening the comprehensive management of concomitant diseases of breast Cancer: 2618 Glycolipid Project
10.3760/cma.j.issn.115807-20200225-00041
- VernacularTitle:关注乳腺癌伴随疾病全方位管理之"2618糖脂工程"
- Author:
Lingquan KONG
1
;
Shu LI
;
Juan WU
;
Shen TIAN
;
Hao LI
;
Hongyuan LI
;
Guosheng REN
;
Kainan WU
Author Information
1. 重庆医科大学附属第一医院内分泌乳腺外科 400016
- From:Chinese Journal of Endocrine Surgery
2020;14(2):89-93
- CountryChina
- Language:Chinese
-
Abstract:
In Oct. 2016, the Central Committee of the Communist Party of China and the State Council issued the "Outline for Healthy China 2030" , which planned to achieve chronic disease management for the entire population and the overall 5-year survival rate of cancer increasing by 15% by 2030. In Jan. 2019, the "2618 Glycolipid Project" was launched, which promoted the comprehensive management of blood glucose, blood pressure and blood lipids in the grassroots. Breast cancer is the most common malignant tumor in women. With the improvement of its diagnosis and treatment, most of the patients survive for a long time in a state of chronic disease. Diabetes, dyslipidemia, and hypertension have a higher prevalence in breast cancer patients, and are most common concomitant diseases of breast cancer. Breast cancer patients also have a higher proportion of carotid plaques and carotid intima thickening. However, there is no obvious symptoms, and there is a lack of clinical understanding of its harm, which will inevitably affect the treatment and prognosis of breast cancer patients. This article will explore the significance and implementation of "2618 Glycolipid Project" in the management of patients with breast cancer, in order to further improve the life quality and the prognosis of breast cancer patients.
